Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Abiraterone
Drug ID BADD_D00014
Description Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.
Indications and Usage Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer.
Marketing Status approved
ATC Code L02BX03
DrugBank ID DB05812
KEGG ID Not Available
MeSH ID C089740
PubChem ID 132971
TTD Drug ID D02STN
NDC Product Code 42291-024; 42291-073; 69238-1754; 60219-1754; 60687-455; 17337-0082; 54893-0070; 30007-838; 69238-1165; 60219-1165
UNII G819A456D0
Synonyms abiraterone | 17-(3-pyridyl)androsta-5,16-dien-3beta-ol | CB-7598 | CB 7598 | CB7598
Chemical Information
Molecular Formula C24H31NO
CAS Registry Number 154229-19-3
SMILES CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypokalaemia14.05.03.0020.022890%
Hypophosphataemia14.04.03.0010.001235%
Hypotension24.06.03.002--
Hypovolaemic shock24.06.02.0170.000334%Not Available
Ileus07.13.01.0010.001001%
Incoherent19.10.03.006; 17.02.08.0020.000734%Not Available
Incontinence17.05.01.006; 07.01.06.011; 20.02.02.0040.001869%Not Available
Increased tendency to bruise24.07.06.012; 23.06.01.009; 01.01.03.0050.002836%Not Available
Infection11.01.08.002--Not Available
Initial insomnia19.02.01.005; 17.15.03.0050.002269%Not Available
Insomnia19.02.01.002; 17.15.03.002--
Interstitial lung disease22.01.02.003; 10.02.01.0330.005839%Not Available
Intestinal obstruction07.13.01.0020.002236%Not Available
Intestinal perforation07.04.06.0020.000501%Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.002503%Not Available
Joint swelling15.01.02.0040.016584%Not Available
Ketosis14.01.01.0010.000334%Not Available
Left ventricular failure02.05.02.0010.000334%Not Available
Liver disorder09.01.08.0010.012813%Not Available
Lymphoedema01.09.01.006; 24.09.01.0010.001635%
Lymphopenia01.02.02.002--Not Available
Macular degeneration06.09.03.0010.000334%Not Available
Memory impairment19.20.01.003; 17.03.02.003--
Meningioma17.20.01.005; 16.30.01.0050.000501%Not Available
Menopausal symptoms21.02.02.002--Not Available
Metastases to liver16.22.02.001; 09.04.02.0040.002002%Not Available
Metastases to lung22.08.01.005; 16.22.02.0020.001335%Not Available
Metastases to spine16.22.02.007; 15.09.03.0070.001401%Not Available
Micturition urgency20.02.02.0060.001301%
Middle insomnia19.02.01.003; 17.15.03.0030.003003%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 12 Pages